سعر سوبراكيت 20 كبسولة 2026

Oral hard capsule combining yohimbine, vitamin E, caffeine and nicotinic acid, marketed in Egypt by Rameda for male sexual weakness; listed as cancelled in the source sheet.

• Common: headache, nausea, increased urinary frequency, insomnia, anxiety, restlessness, irritability.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Uncommon: allergic reactions, increased blood pressure and heart rate, palpitations, hypotension, nervousness, dizziness, gastrointestinal complaints, urticaria, sweating, chills, fever, fatigue.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Very rare: tremor, bronchospasm, rash; frequency not known: marked reduction in granulocytes.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)

• Hypersensitivity to yohimbine hydrochloride or any excipient.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Severe hepatic and/or renal impairment.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Heart disease, particularly coronary heart disease or cardiac arrhythmias.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Hypertension or hypotension.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Gastric or intestinal ulcers.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Raised intraocular pressure (glaucoma).General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Psychiatric disorders, especially mood disorders or anxiety; concomitant use of certain psychiatric/neurological or antihypertensive medicines, or alcohol.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)

• In known epilepsy yohimbine may increase the frequency of seizures.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• May worsen existing renal impairment; impaired hepatic function may increase effects and adverse effects.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• Not indicated in patients under 18 years or for female sexual dysfunction.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)
• May impair reactions and ability to drive or operate machinery, more so with alcohol.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)

• ClonidineShould not be combined; the effects of yohimbine and clonidine cancel each other.BASG (Austrian Federal Office for Safety in Health Care)
• AntihypertensivesYohimbine may reduce the effect of blood-pressure-lowering medicines.BASG (Austrian Federal Office for Safety in Health Care)
• Tricyclic and other antidepressantsEffects and adverse effects may be increased; clomipramine raises yohimbine plasma levels.BASG (Austrian Federal Office for Safety in Health Care)
• AmphetaminesConcomitant use strongly discouraged (possible potentiation).BASG (Austrian Federal Office for Safety in Health Care)
• OpioidsYohimbine may enhance opioid effects.BASG (Austrian Federal Office for Safety in Health Care)
• AlprazolamYohimbine reduces the effect of alprazolam.BASG (Austrian Federal Office for Safety in Health Care)
• AlcoholAlcohol must not be consumed during use.BASG (Austrian Federal Office for Safety in Health Care)

• Because of its indication (male erectile dysfunction), use in women is not applicable; animal studies showed no effect on fertility.General active-ingredient information · BASG (Austrian Federal Office for Safety in Health Care)